
Sign up to save your podcasts
Or


What if we could change treatment before scans show progression? In this episode of CHM Conversations, Dr. Jason Mouabbi and Dr. Ahmed Elkhanany explore the impact of ESR1 mutations and the clinical shift toward "molecular progression" in HR+ mBC.
The discussion breaks down the SERENA-6 trial and how early ctDNA detection may allow clinicians to switch therapy before radiologic progression occurs. Dr. Mouabbi and Dr. Elkhanany highlight how precision oncology is reshaping strategy, specifically looking at how oral SERDs like camizestrant can extend endocrine sensitivity and delay more intensive treatments.
The clinicians also examine the transition away from traditional RECIST-based decision-making. They address the practicalities of routine ctDNA testing, patient communication, and what community oncologists should expect as these biomarker-driven approaches move closer to standard practice.
A compelling discussion on the future of proactive intervention and earlier care in metastatic breast cancer.
🎧 Watch more expert-led oncology conversations from CHM Conversations.
#BreastCancer #HRPositive #Oncology #ESR1 #ctDNA #SERENA6 #Camizestrant #EndocrineTherapy #PrecisionOncology #MedicalOncology #CommunityHealthMedia
–
Thanks for watching!
Our podcasts are also available on:
• Spotify - https://spotf.fi/chm-podcast
• Amazon Music - https://amazn.so/chm-podcast
• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248
• Castbox - https://castbox.fm/vh/6735434
• Goodpods - https://goodpods.com/profile/chm-111066
• iHeartRadio - https://iheart.com/podcast/291542082
• Pocket Casts - https://pca.st/3ncdh11o
–
Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.
We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.
We specialize in:
• Peer to peer interviews, panels & round-tables
• Curated live events & conferences
• Professional in-depth content & research updates
• Interactive learning modules & webinars
• Live & on-demand webcasts & podcasts
Learn more about us here - https://communityhealth.media
By Community Health MediaWhat if we could change treatment before scans show progression? In this episode of CHM Conversations, Dr. Jason Mouabbi and Dr. Ahmed Elkhanany explore the impact of ESR1 mutations and the clinical shift toward "molecular progression" in HR+ mBC.
The discussion breaks down the SERENA-6 trial and how early ctDNA detection may allow clinicians to switch therapy before radiologic progression occurs. Dr. Mouabbi and Dr. Elkhanany highlight how precision oncology is reshaping strategy, specifically looking at how oral SERDs like camizestrant can extend endocrine sensitivity and delay more intensive treatments.
The clinicians also examine the transition away from traditional RECIST-based decision-making. They address the practicalities of routine ctDNA testing, patient communication, and what community oncologists should expect as these biomarker-driven approaches move closer to standard practice.
A compelling discussion on the future of proactive intervention and earlier care in metastatic breast cancer.
🎧 Watch more expert-led oncology conversations from CHM Conversations.
#BreastCancer #HRPositive #Oncology #ESR1 #ctDNA #SERENA6 #Camizestrant #EndocrineTherapy #PrecisionOncology #MedicalOncology #CommunityHealthMedia
–
Thanks for watching!
Our podcasts are also available on:
• Spotify - https://spotf.fi/chm-podcast
• Amazon Music - https://amazn.so/chm-podcast
• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248
• Castbox - https://castbox.fm/vh/6735434
• Goodpods - https://goodpods.com/profile/chm-111066
• iHeartRadio - https://iheart.com/podcast/291542082
• Pocket Casts - https://pca.st/3ncdh11o
–
Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.
We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.
We specialize in:
• Peer to peer interviews, panels & round-tables
• Curated live events & conferences
• Professional in-depth content & research updates
• Interactive learning modules & webinars
• Live & on-demand webcasts & podcasts
Learn more about us here - https://communityhealth.media